Scarica l'app Stockscreener
8.32
3.73%
0.27
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.05
Aprire:
$7.87
Volume 24 ore:
17,012
Relative Volume:
0.45
Capitalizzazione di mercato:
$89.32M
Reddito:
$49.98M
Utile/perdita netta:
$-9.64M
Rapporto P/E:
-11.72
EPS:
-0.71
Flusso di cassa netto:
$-4.86M
1 W Prestazione:
+33.17%
1M Prestazione:
+31.50%
6M Prestazione:
+20.84%
1 anno Prestazione:
+70.06%
Intervallo 1D:
$7.87
$8.3423
Intervallo di 1 settimana:
$6.30
$8.5799
Portata 52W:
$3.6001
$11.99
Champions Oncology Inc Stock (CSBR) Company Profile
Nome
Champions Oncology Inc
Settore
Industria
Telefono
410-369-0365
Indirizzo
855 N. WOLFE STREET, BALTIMORE, NJ
Confronta CSBR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
8.33 | 89.32M | 49.98M | -9.64M | -4.86M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.68 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
515.93 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.64 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.30 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.43 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-12 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2019-11-18 | Iniziato | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Borsa (CSBR) Ultime notizie
Champions Oncology: Biological IP Is The Real AssetNot Preclinical Services - Seeking Alpha
Champions Oncology, Inc.'s (NASDAQ:CSBR) 11% gain last week benefited both private equity firms who own 30% as well as insiders - Yahoo Finance
After A Standout Q3, What's On The Horizon For Champions Oncology? - RTTNews
"STRONGER TOGETHER": SWITZERLAND CHAMPIONS INTERNATIONAL PARTNERSHIPS AS KEY TO ACCELERATED INNOVATION", ONCE AGAIN SWITZERLAND IS SHOWCASING ITS BIOTECH EXCELLENCE AT BIO INTERNATIONAL IN BOSTON 1 - Yahoo
How To Trade (CSBR) - news.stocktradersdaily.com
Humanized Mouse and Rat Model Market worth US$409.8 million - openPR.com
Humanized Mouse and Rat Model Market worth US$409.8 million in 2030 with 8.2% CAGR | MarketsandMarkets™ - Barchart.com
(CSBR) Long Term Investment Analysis - news.stocktradersdaily.com
Positive Sentiment Still Eludes Champions Oncology, Inc. (NASDAQ:CSBR) Following 26% Share Price Slump - simplywall.st
Sixth Annual Champions Gala Raises Money for Lehigh Valley Topper Cancer Institute - Lehigh Valley Health Network
Heartland Oncology and Hematology Oncologist Named 2025 Advocacy Champion by the Association for Clinical Oncology (ASCO) - Seeking Alpha
Leading Oncologist Wins ASCO's Top Advocacy Award for Fighting Cancer Care Barriers - Stock Titan
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million - ACCESS Newswire
Where are the Opportunities in (CSBR) - news.stocktradersdaily.com
Champions Oncology Says It Has Obtained License to Use Radioactive Materials in Preclinical Studies - marketscreener.com
CSBR Secures License for Radioactive Material Use in Preclinical Studies | CSBR Stock News - GuruFocus
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House - Bellingham Herald
Press Release Distribution & PR Platform - ACCESS Newswire
Champions Oncology Unlocks Next-Gen Cancer Treatment Capabilities with Strategic Radiotherapy License - Stock Titan
Champions Oncology Reports Record Quarterly Revenue of $9.5 Million - ACCESS Newswire
Champions Oncology Reports Quarterly Revenue of $12.9 Million - ACCESS Newswire
Champions Oncology Reports Quarterly Revenue of $12.0 Million - ACCESS Newswire
Champions Oncology (CSBR) Partners with Turbine to Boost Drug Di - GuruFocus
Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine - Stock Titan
Turbine Launches the World’s First Virtual Lab Using Cell Simulations - Business Wire
Humanized Mouse and Rat Model Market worth US$409.8 million in 2030 with 8.2% CAGR | MarketsandMarkets - The Malaysian Reserve
Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their respectable 47% return over the last year - Yahoo
I-Apollo Hospitals, yethula i-“Cancer Champions United” isinyathelo esiyingqayizivele sokunikeza amandla Abasinde Ngomdlavuza! - Apollo Hospitals
Patient Derived Xenograft Model Market Future Business - openPR.com
Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019 - ACCESS Newswire
Investors Give Champions Oncology, Inc. (NASDAQ:CSBR) Shares A 28% Hiding - simplywall.st
American Battery Technology boosts recycled battery output - Investing.com
Apollo Hospitals, yakhazikitsa "Cancer Champions United" njira yapadera yopatsa mphamvu Opulumuka Khansa! - Apollo Hospitals
Pre-market Movers: PTPI, ACON, HUMA, TNON... - RTTNews
CHAMPIONS ONCOLOGY, INC. SEC 10-Q Report - TradingView
Champions Oncology Third Quarter 2025 Earnings: EPS: US$0.33 (vs US$0.19 loss in 3Q 2024) - Yahoo Finance
Champions Oncology target raised to $12 at Craig-Hallum By Investing.com - Investing.com Canada
Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2025 Earnings Call Transcript - MSN
Earnings call transcript: Champions Oncology Q1 2025 earnings beat expectations By Investing.com - Investing.com South Africa
Champions Oncology Inc Azioni (CSBR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.59%
0.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):